3PBIOVIAN awarded at the CDMO Leadership Awards 2025
3PBIOVIAN, a leading Contract Development and Manufacturing Organization (CDMO) with locations in Pamplona (Spain) and Turku (Finland), has been awarded the prestigious CDMO Leadership Award 2025 in the "Cell & Gene Therapy International" category. This award recognizes the excellence of the services that 3PBIOVIAN provides to the Advanced Therapies industry, solidifying its position as a leader in the international sector.
The 14th edition of the Leadership Awards Ceremony took place on March 19, 2025, in New York. During this ceremony, 3PBIOVIAN was announced to receive the Leadership Award 2025 in the “Cell & Gene Therapy International” category. This recognition underscores 3PBIOVIAN’s commitment and expertise in the field of advanced therapies, areas that are revolutionizing the treatment of previously incurable diseases. Thanks to its robust technological capabilities, the experience of its highly qualified team, as well as a client-oriented and innovative approach, the company has demonstrated a successful track record in the manufacturing of cutting-edge therapeutic products. In addition, 3PBIOVIAN was nominated as a finalist in the “Biologics International” category. This showcases the company’s extensive expertise in the biotech industry, supporting clients from all around the world on their journey from early development to commercialization.
The CDMO Leadership Awards are one of the most prestigious distinctions within the CDMO industry, given to organizations that stand out for their ability to deliver exceptional solutions, operational efficiency, and a client-oriented approach in pharmaceutical manufacturing. The awards are presented annually by Outsourced Pharma and Life Science Connect, based on independent surveys of leaders in the biopharmaceutical and biotechnology industries who evaluate the performance of contract development and manufacturing organizations
(CDMOs) in key areas such as facilities, scientific expertise, manufacturing capability, and quality management.
The CDMO evaluation was based on a proprietary scoring system blended Net Promoter Scores (NPS) with a “Top 3 Ranking” from survey respondents.
Dámaso Molero, Corporate CEO, stated: “We are deeply grateful to receive this prestigious award, which reflects the constant effort and dedication of our entire team. We would like to express our sincere gratitude to all our clients, whose trust and support have been essential to achieving this valuable recognition.”
This award strengthens 3PBIOVIAN’s positioning as a key strategic partner for global companies seeking to bring their advanced therapies to market efficiently and safely.
More information about CDMO Leadership Awards: https://cdmoleadershipawards.com/
Axplora Group
ProBioGen
Rentschler Biopharma SE